Answers are grounded in this paper and cite their sources.
Nicotinamide adenine dinucleotide (NAD⁺) is a central redox cofactor that supports cellular metabolism, redox balance and signal transduction. Nicotinamide phosphoribosyltransferase (NAMPT) catalyzes the rate-limiting step of NAD⁺ salvage pathway in both malignant and non-malignant cells of the tumor microenvironment (TME). Whilst direct restriction of NAD⁺ metabolism in cancer cells has yielded limited clinical benefit, emerging evidence reveals that NAMPT shapes antitumor immunity by reprogramming immune cell function and the metabolic landscape of the TME. Parallel advances in medicinal chemistry, including bifunctional inhibitors, drug-delivery systems and proteolysis-targeting chimeras (PROTACs) are enabling more selective NAMPT-targeted agents. This review examines the context-dependent roles of NAMPT across immune and stromal compartments of the TME and evaluates emerging therapeutic approaches, highlighting their potential to overcome current limitations and advance NAMPT-targeted immunotherapy.
No takes yet. Share an insight, caveat, or question.
Wei et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: